Petros Pharmaceuticals Inc. (NASDAQ: (PTPI) stock gained by 64.57% at the last close whereas the PTPI stock price fell by 15.63% in the after-hours trading session. Petros Pharmaceuticals is dedicated to establishing a world-class specialized men’s health firm by discovering, producing, acquiring, and commercializing novel therapies for men’s health challenges.
PTPI stock’ Update
As a result of an exclusive digital health marketing deal with Hims & Hers Health, Petros Pharmaceuticals reports a 476 percent increase in STENDRA tablet sales year over year. It’s a multi-specialty telehealth system that aims to provide consumers with modern, individualized health and wellness experiences. The firms also announced that more STENDRA dosages will be available through the Hims & Hers platform, extending the cooperation even further.
STENDRA is now available through the Hims platform in 50mg, 100mg, and 200mg pills, which are all authorized by FDA. Customers who want to buy a prescription from Hims & Hers must first undergo a virtual assessment with a licensed healthcare professional on the platform to see if the procedure is medically necessary.
Only about a quarter of the approximately 30 million men in the United States with erectile dysfunction have undergone oral erectile dysfunction therapy, according to estimates.
Fady Boctor, Petros Pharmaceuticals’ President and Chief Commercial Officer commented that,
Their continuous partnership with Hims helps to promote an industry-leading telehealth platform that enables people to enquire about and treat erectile dysfunction in a confidential and comfortable manner. They’re thrilled to broaden their relationship with Hims and improve access to STENDRA through this crucial channel, which has seen considerable year-over-year growth in STENDRA tablet sales.
Dr. Patrick Carroll, Chief Medical Officer at Hims & Hers stated that,
Offering STENDRA to their clients has aided in the strengthening of their platform and has also helped them in achieving their aim of offering more access to tailored care. They are overjoyed to be able to assist and help so many men who suffer from erectile dysfunction. They’re excited to grow their partnership with Petros by offering more dosage options at accessible costs through their platform, allowing even more people to benefit from high-quality, individualized care.
